Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - PRECIGEN, INC. | xon-20161231exx322.htm |
| EX-32.1 - EXHIBIT 32.1 - PRECIGEN, INC. | xon-20161231exx321.htm |
| EX-31.2 - EXHIBIT 31.2 - PRECIGEN, INC. | xon-20161231exx312.htm |
| EX-31.1 - EXHIBIT 31.1 - PRECIGEN, INC. | xon-20161231exx311.htm |
| EX-23.1 - EXHIBIT 23.1 - PRECIGEN, INC. | xon-20161231exx231.htm |
| EX-21.1 - EXHIBIT 21.1 - PRECIGEN, INC. | xon-20161231exx211.htm |
| EX-10.3 - EXHIBIT 10.3 - PRECIGEN, INC. | xon-20161231exx103.htm |
| 10-K - 10-K - PRECIGEN, INC. | xon-20161231x10k.htm |
Exhibit 23.2
Consent of independent registered public accounting firm
We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-190614, 333-196840, 333-205642, and 333-213065) and on Form S-3 (No. 333-198598) of Intrexon Corporation of our report dated February 24, 2016, relating to the financial statements of ZIOPHARM Oncology, Inc. appearing in the Annual Report on Form 10-K of Intrexon Corporation for the year ended December 31, 2016.
/s/ RSM US LLP
Boston, Massachusetts
March 1, 2017